Breaking News

Merck KGaA Licenses Four Vertex Oncology Programs

Gains worldwide development and commercialization rights to assets targeting DNA damage and repair

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Vertex Pharmaceuticals has entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for worldwide development and commercialization rights to four cancer R&D programs. Merck KGaA will license two clinical-stage programs targeting DNA damage and repair, along with two preclinical programs. Vertex will receive an upfront payment of $230 million, in addition to royalties on future sales. Merck KGaA will be responsible for the development and commercialization of all the programs. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters